COVID-19是由SARS-CoV-2造成的,并导致了全球健康危机,这使得迫切需要开发疫苗以防止其在公众中传播。辉瑞-BioNTechCOVID-19是紧急使用授权(EUA)疫苗之一。这种疫苗对SARS-CoV-2病毒有效;尽管如此,接受者经常报告副作用。这种疫苗的接受者经历了各种各样的副作用,如疲劳和头痛。然而,疫苗接种后出现不同程度的皮肤爆发和受累。对COVID-19疾病疫苗接种后的皮肤病爆发认识不足。疫苗接种后引发的皮肤病学表现在临床背景和患者的人口统计学特征上有所不同。唯一不变的因素是各种临床和组织病理学关系,以建立疫苗接种后皮肤爆发的诊断。在这里,我们报告了1例18岁男性T细胞急性淋巴细胞性淋巴瘤(ALL)自2018年8月以来缓解,并伴有其他合并症.在施用第一剂Pfizer-BioNTechCOVID-19疫苗后,患者出现瘙痒性湿疹疹,表现为成组的红斑-紫罗兰色丘疹泡状病变,上肢和下肢有细鳞片。这些爆发在接种疫苗两天后开始。在接受第二剂辉瑞-BioNTechCOVID-19疫苗21天后,这种爆发变得普遍。怀疑是药物引起的水泡喷发的临床怀疑;因此,活检显示糜烂和混合炎性细胞浸润.从临床和组织病理学相关性来看,证实了辉瑞-BioNTechCOVID-19疫苗接种后的水疱爆发。然而,不能排除其他诊断,但是从临床-组织病理学联系来看,疫苗引起的爆发可能是罪魁祸首。报告对于了解新出现的疾病和诸如疫苗接种之类的反作用后这种皮肤病学表现的性质至关重要。皮肤病学表现被模糊地识别;因此,通过报告与本报告中的案例类似的案例,将有更多的数据来了解这种喷发的性质和根本原因。
COVID-19 is inflicted by SARS-CoV-2 and resulted in a global health crisis that necessitated the urgency of vaccine development to prevent its spreading among the public. Pfizer-BioNTech COVID-19 is one of the emergency use authorized (EUA) vaccines. This vaccine is efficacious against the SARS-CoV-2 virus; nonetheless, recipients have frequently reported side effects. Recipients of this vaccine experienced miscellaneous side effects like fatigue and headache. However, cutaneous eruptions of varying degrees of severity and involvements have been manifesting post-vaccination. Dermatological eruptions following vaccination against COVID-19 disease are poorly recognized. Dermatological manifestations triggered post-vaccination differ in the clinical context and patient\'s demographic features. The only constant factor is various clinical and histopathological relations to establish the diagnosis of cutaneous eruption post-vaccination. Herein, we report a case of an 18-year-old male with T-cell acute lymphocytic lymphoma (ALL) in remission since August 2018 and other comorbidities. After the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine, the patient developed pruritic eczematous eruption presenting as grouped erythematous-violaceous
papulovesicular lesions with fine scales over his upper and lower extremities. These eruptions started two days after the administration of the vaccine. This eruption became generalized 21 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine. Clinical suspicion of the drug-induced vesicular eruption was suspected; thus, a biopsy was obtained and showed erosions and mixed inflammatory cell infiltrate. From a clinical and histopathological correlation, vesicular eruption following vaccination with Pfizer-BioNTech COVID-19 was confirmed. Nevertheless, other diagnoses cannot be ruled out, but from the clinical-histopathological association, the vaccine-inflicted eruption is the likely culprit. Reports are crucial to understanding the nature of such dermatological manifestation after emerging diseases and counteractions like vaccinations. The dermatological manifestations are vaguely recognized; thus, by reporting on the cases similar to the case in this report, more data will be available to understand the nature and underlying cause of such eruptions.